joining you, everyone Thank for us.
that few change product on that the extended date has commercial in an proprietary for application a We significant no and this the our update have topics launch approved with the drug other like now are shortly. today September there discuss we year. our due from product the EM-XXX a on and action confident to will and of target later submission, name XX. remain number I'd FDA We've told a developments weeks to specifically for been outstanding, pipeline our first to orphan very progress start our update deficiencies be including exciting on to Eton's plans
resulted methanol has the Left high is ERs been sanitizer XXX this of FDA launching serious this the methanol DS-XXX very to and of sanitizers impurity a we and Therefore, untreated poisoning the recalls our July a annually. grade poisoning words quality. product nation. an serious demand Dehydrated company production strict hand an for limits levels estimated million death. the hand has cause The We can sanitizers current in to issued and look our blindness due our opportunity – also the over terms of communicate, and Alcohol of both year. regarding represents believe situation, This Now our many significant in There’s across moving low and methanol. submitted different also toxic DS-XXX excess for outcome in few antidote to a for of Unfortunately, to over has has skyrocketed. as DS-XXX to COVID-XX adverse events market Injection in a very future. forward with is near be $XXX product, employees
We expect for to submitted be one zonisamide. players patent time. pending of which in we Also is NDA a in this of period of for ET-XXX, our July, only liquid formulation two market the prolonged an
and closer this neurologists three liquid to step one reaching We product are is be epilepsy interest the on with have along to strong and from topiramate. of market. oral lamotrigine products our Zonisamide received excited one
us three We NDA months, next year. epilepsy launch expect in coming products to file topiramate the which allow should all the to
FDA and of product a the expect year. for many to launches into these as is this in With go company we and expected as later translate branded size. the are to between year, unprecedented five of submissions products additional have we now two now to submitted truly end which six filings, submissions These next our
staff. but April COVID-XX of weigh directors started from sales to with to updates, with Biorphen. Unfortunately, on Biorphen, I’d volumes continue representatives to and to policies commercial lows, continues surgical March restrict pharmacy rebound visiting have procedures and our sales hospital like slightly Turning start and from
significantly promotional overcome our the process and Biorphen year. targeting expected campaigns in new we challenges sales new this of are driving half the of are to created has to plan second a implementing adjusting this in higher these While adoption, drive that strategies for are and challenge
catalyst adoption our be presentation. vial Biorphen Another launch to of the will key
submit a later which vial pace supplement on We’re the prior XXXX. this us approval to early year, to will launch allow
from to be resistant to long-term hear institutions next use that feedback us We believe but market achieve will opportunity. vial unit than continue what are efferent, ready support, more estimate XX fully of we fennel We the X capturing million year help many utilizing to of goal launch our ampules. to million a
the product product of should of from Alkindi partners for we regarding candidate Based under approved Sprinkle, is words be which an FDA Alkindi therapy Sprinkle adrenal insufficiency. orphan review as a received on the with in today, communications, few September believe revenue XX. the review the our a pipeline. be we pediatric to its for date on Now, the treatment largest replacement drug our believe PDUFA FDA
approval. We we drugs and shortly launch to commercial ordered added have in we orphan have expect vast in with experience its launching inventory, staff a position launch ultra to after be
stakeholders of engaged the pediatric community. key these part activities, and we have prelaunch with As endocrinology
are Just an last advisory positive industry waiting leaders was the and with and week, in to overwhelmingly Alkindi’s endocrinology anxious they feedback approval. panel the held we
over With for and terms, commercial that more we available able to This SWK hearing are invest flexibility the capacity launch, be the facility. metrics. will financial position major and these Due a with product new than we of a the in with the announce our in of company. for progress convinced experienced approval month. strong will be and were pleased with am available provides to our have untapped next of I performance launches. already million. renegotiate continue a team pursue reached year, growth facility. endocrinologists and the Alkindi opportunities $XX total million as as us prepare that ever Holdings renegotiation also after Under last that success to from even prior our we we to favorably option relationship credit increased to existing our $X pipeline to leading capital more assembled Alkindi have quarter of amendment our our end in we than expanded the greater credit facilities the we we’ve strong amended were this cash now we rate be We will reduced certain But interest when expect Today,
open I’d Q&A, coming up the team’s achievements how months how for I our like quarters. future we of over reiterate excited to past it the and proud am Before Eton’s over for
that and three the we have spent to five to fruits we end candidates that, of next before up are company Operator? call With like the we have reach realizing to the years XXXX. deliver currently groundwork earnings submitted progressing to now year, filings labor. profitability for the to brink the significant We for now would year. the to With next focused our revenue and pipeline aggressively more importantly, begin FDA, on of the drugs on laid NDA questions. My is of open your goal
